IP Library Granted Patent US 11,254,916
Granted Patent B2
US 11,254,916 · App. 16/445,124 · Granted Feb 22, 2022

Methods of making and using PDX1-positive pancreatic endoderm cells

Inventors: Kevin A. D'Amour (San Diego, CA); Anne Bang (San Diego, CA); Emmanuel E. Baetge (Encinitas, CA)
Assignee: ViaCyte, Inc.
C12N5/0676A61K35/39C12N5/0678C12N2500/38C12N2501/10C12N2501/105C12N2501/115C12N2501/119C12N2501/12C12N2501/15C12N2501/16C12N2501/33C12N2501/335C12N2501/385C12N2501/41C12N2501/415C12N2501/42C12N2501/58C12N2501/734C12N2501/999C12N2506/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,254,916
App. No.
16/445,124
Granted
Feb 22, 2022
Kind
B2
Abstract

Disclosed herein are cell cultures and enriched cell populations of endocrine precursor cells, immature pancreatic hormone-expressing cells and mature pancreatic hormone-expressing cells. Also disclosed herein are methods of producing such cell cultures and cell populations.

Claims (11)

1. An in vitro method of making a population of human pancreatic and duodenal homeobox (PDX1)-positive pancreatic endoderm cells, comprising:

a) obtaining a population of human definitive endoderm cells;

b) contacting the population of human definitive endoderm cells with an effective amount of a growth factor, wherein the growth factor is a member of the fibroblast growth factor (FGF) family, thereby obtaining a population of human foregut endoderm cells; and

c) contacting the population of human foregut endoderm cells with an effective amount of a retinoid, thereby making the population of human PDX1-positive pancreatic endoderm cells.

2. The method of claim 1 , wherein the member of the FGF family is FGF1, FGF2, FGF3, FGF4, FGF5, FGF6, FGF7, FGF8, FGF9, FGF10, FGF11, FGF12, FGF13, FGF14, FGF15, FGF16, FGF17, FGF18, FGF19, FGF20, FGF21, FGF22, or FGF23.

3. The method of claim 1 , further comprising contacting the population of human PDX1-positive pancreatic endoderm cells with a gamma secretase inhibitor.

4. The method of claim 3 , wherein the gamma secretase inhibitor is DAPT.

5. The method of claim 1 , wherein the population of human PDX1-positive pancreatic endoderm cells does not substantially express ghrelin, glucagon, insulin, or islet amyloid polypeptide (IAPP).

6. The method of claim 1 , further comprising contacting the population of human PDX1-positive pancreatic endoderm cells with nicotinamide (NIC), exendin 4 (Ex4), hepatocyte growth factor (HGF), insulin-like growth factor (IGF), or combinations thereof.

7. The method of claim 1 , wherein the retinoid is retinoic acid.

8. The method of claim 7 , wherein the retinoic acid is at a concentration of about 1 nM to about 10 μM.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 3, 2019
From: D'AMOUR, KEVIN A; BANG, ANNE; BAETGE, EMMANUEL E
To: CYTHERA, INC.
Reel/Frame 049666/0110 →
MERGER AND CHANGE OF NAME Recorded Jul 3, 2019
From: CYTHERA, INC.; VIACYTE, INC.
To: VIACYTE, INC.
Reel/Frame 049693/0159 →
Continuity (8)
Continuation 15173316 · Jun 3, 2016
Continuation 14072491 · Nov 5, 2013
Continuation 13275274 · Oct 17, 2011
Division 11681687 · Mar 2, 2007
Provisional Application 60852878 · Oct 18, 2006
Provisional Application 60833633 · Jul 26, 2006
Provisional Application 60778649 · Mar 2, 2006
Related Publication 20190359943A1 · Nov 28, 2019